Huntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potentially transformative treatment for the devastating neurodegenerative condition.
Boston-based Skyhawk says that the first patient has been dosed in the FALCON-HD trial evaluating SKY-0515, an investigational oral RNA...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?